Physician profile
Labronz C Davis
NPI 1003857749
$9,960.47
in general payments reported to CMS, 2019-2025
40 companies · $820 in 2025
The $820 reported for 2025 was more than what 82% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,802 · 2020: $2,374 · 2021: $2,658 · 2022: $453 · 2023: $432 · 2024: $421 · 2025: $820.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,673.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,672.94 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals Lp | $1,139.20 | 2019-2021 | |
| Lilly USA, LLC | $817.84 | 2019-2025 | Zepbound |
| Boston Scientific Corporation | $816.52 | 2021-2025 | Watchman Flx |
| Glaxosmithkline, LLC. | $785.50 | 2019-2021 | |
| Pfizer INC. | $640.83 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $634.73 | 2019-2024 | Gardasil, Capvaxive, Gardasil 9 |
| Boehringer Ingelheim Pharmaceuticals, INC. | $617.75 | 2019-2021 | |
| Novo Nordisk INC | $579.06 | 2019-2021 | |
| Dexcom, INC. | $427.98 | 2022-2025 | Dexcom G6 Transmitter |
| Abbvie INC. | $379.76 | 2019-2022 | |
| Allergan, INC. | $356.41 | 2019-2020 | |
| Nevro Corp. | $355.97 | 2022-2024 | Senza |
| Astellas Pharma US INC | $313.22 | 2019-2025 | Veozah |
| Esperion Therapeutics, INC. | $203.72 | 2021 | |
| Novartis Pharmaceuticals Corporation | $186.01 | 2019-2021 |
Show all 40 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Labronz Davis listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.